S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

BCRX BioCryst Pharmaceuticals Inc

4.375

0.245 (5.93%)

Last Updated: 00:31:52

Delayed by 15 minutes

BioCryst Pharmaceuticals EPS misses by $0.08, beats on revenue

To read the full story on Seeking Alpha, click here.

BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more BioCryst Pharmaceuticals Charts.

BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more BioCryst Pharmaceuticals Charts.

BioCryst Pharmaceuticals Inc News

BioCryst to Report First Quarter 2024 Financial Results on May 6
Monday 22 April 2024 (1 week ago) • GlobeNewswire Inc.

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
Wednesday 17 April 2024 (2 weeks ago) • GlobeNewswire Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 3 April 2024 (4 weeks ago) • GlobeNewswire Inc.

BioCryst to Present at Upcoming Investor Conferences
Tuesday 26 March 2024 (1 month ago) • GlobeNewswire Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 5 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 26 February 2024 (2 months ago) • Edgar (US Regulatory)

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
Monday 26 February 2024 (2 months ago) • GlobeNewswire Inc.

U.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices Retreat
Monday 26 February 2024 (2 months ago) • IH Market News

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
Friday 23 February 2024 (2 months ago) • GlobeNewswire Inc.

More BioCryst Pharmaceuticals Inc News Articles

Sterling vs AUD

S&P ASX 300 Metals and M...

Verizon Communications

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions